The association between the 844ins68 polymorphism in the CBS gene and breast cancer

Martha Patricia Gallegos-Arreola1, Luis Eduardo Figuera-Villanueva2, Adriana Ramos-Silva1,3, Efrain Salas-Gonzalez4, Ana Maria Puebla-Perez5, Valeria Peralta-Leal6, Jose Elias Garcia-Ortiz2, Ingrid Patricia Davalos-Rodriguez2, Guillermo Moises Zuniga-Gonzalez7

Abstract

Introduction: The cystathionine beta synthase (CBS) gene plays an important role in homocysteine metabolism because it catalyzes the first step of the transsulfuration pathway, during which homocysteine is converted to cystathionine. Polymorphisms of CBS have been associated with cancer.

Material and methods: We examined the role of the 844ins68 polymorphism by comparing the genotypes of 371 healthy Mexican women with the genotypes of 323 Mexican women with breast cancer (BC).

Results: The observed genotype frequencies for controls and BC patients were 1% and 2% for Ins/Ins, 13% and 26% for W/Ins, and 86% and 72% for W/W, respectively. We found that the odds ratio (OR) was 2.2, with a 95% confidence interval (95% CI) of 1.5–3.3, p = 0.0001. The association was also evident when comparing the distribution of the W/Ins-Ins/Ins genotypes in patients in the following categories: 1) menopause and high γ-glutamyl-transferase (GGT) levels (OR of 2.17, 95% CI: 1.17–4.26, p = 0.02), 2) chemotherapy response and high lactate dehydrogenase (LDH) levels (OR 2.2, 95% CI: 1.98–4.4, p = 0.027), 3) chemotherapy response and high GGT levels (OR 2.46, 95% CI: 1.2–4.8, p = 0.007), and 4) body mass index (BMI) and III–IV tumor stage (OR 3.2, 95% CI: 1.2–8.3, p = 0.013).

Conclusions: We conclude that the genotypes W/Ins-Ins/Ins of the 844ins68 polymorphism in the CBS gene contribute significantly to BC susceptibility in the analyzed sample from the Mexican population.

Key words: 844ins68, T833C, polymorphism, breast cancer, Mexican population.

Introduction

Breast cancer (BC) is a disease characterized by the presence of uncontrolled cell growth in the ducts (ductal carcinoma) or lobules (lobular...
The association between the 844ins68 polymorphism in the CBS gene and breast cancer

carcinoma) of the mammary gland, and the tumor can invade the surrounding tissues of the breast in later stages. Most breast tumors are invasive or infiltrating, and they are classified by the American Joint Committee on Cancer (AJCC) by several defined stages [1]. Breast cancer is one of the most common diseases in developing countries in the world. It is estimated that there are millions of symptomatic women affected by BC and millions more currently asymptomatic who will develop cancer [2]. Incidence rates are variable in different ethnic groups with 122.6 per 100,000 cases in white women, 118 per 100,000 cases among blacks, 92.8 per 100,000 cases in Hispanics, 87.9 per 100,000 cases in Asian/Pacific Islanders, and 65.6 per 100,000 in American Indian/Alaskan Natives [3]. In many countries around the world, and particularly in Mexico, the incidence of BC has increased within the last 6 years, and it is now one of the main causes of death in reproductive age females. The mortality incidence rate since 2006 has increased, and has surpassed the mortality rate of cervical cancer. The mortality rate in Mexico was 4,854 deaths in 2009 [4] and has been projected to increase to over 16,500 deaths per year by 2020. Only 10% of all cases are detected at stage I. The state of Jalisco has one of the highest mortality rates for BC [5]. Breast cancer is considered to be a multifactorial disease, and BC might result from a combination of abnormal protein interactions and environmental factors [6]. Previous research has implicated a variety of risk factors for BC, including age, early menarche, menopause, oral contraceptive use, cigarette smoking, alcohol consumption, a family history of BC, breast fibrosis, nulliparity, breastfeeding, ethnicity, nutrition and genetics [7]. Elucidating the genetic variants among different ethnic groups could help to explain the progression of cancer, as well as chemotherapy response.

The CBS gene, which is located on chromosome 21q22.3, codes for an enzyme that participates in the folate pathway and catalyzes the transsulfuration of homocysteine and serine to cystathionine as a cysteine precursor [8]. CBS deficiency can modify the stability of a domain or residue in the hydrophobic core, which leads to degradation of the CBS protein. This produces elevated levels in the plasma of homocysteine and methionine, which consequently alter methylation processes [8]. Therefore, a CBS deficiency may have a potential impact on oncogenesis (Figure 1) [9].

The CBS gene has a large number of reported mutations and polymorphisms [8]. The 844ins68 polymorphism at position 844 in the CBS gene generates an alternative splicing site that disrupts the protein, which decreases the functional activity of CBS. This polymorphism was initially described in a homocystinuric patient [10]. The 844ins68 polymorphism segregates in cis with the T833C mutation [11]. Different studies have found variability in the allelic frequency among ethnic groups, and homozygosity for the 68-bp insertion is rare in population studied [12]. Different populations have also shown variability in the frequency of the heterozygous genotype, with the highest prevalence of 66 at 20% being described in sub-Saharan African [13] and British populations [14]. The median prevalence of 17 at 11% was found in Brazil [9], Holland [15], Italy [16], Spain [17], Ethiopia [13], and the United States [11]. A low prevalence of the heterozygous genotype of 10 at 1% was observed in India [18], Czechoslovakia [19], South Iran [20], China [21], Colombia [22], and Chile [23]. The 844ins68 allele was not observed in Japan or Indonesia [13]. Although the biological impact of the 844ins68 polymorphism in the CBS gene is not clear, it has been associated with different pathologies, including cardiovascular defects, neural tube defects, and cancer [9, 12, 16, 17, 21, 22, 24, 25]. However, several of these studies that examined the connection between the 844ins68 polymorphism and BC did not reveal any statistically significant associations [26, 27].
The aim of this study was to determine the association between the 844ins68 polymorphism in the CBS gene and Mexican women with BC.

Material and methods

DNA was extracted from peripheral blood lymphocytes using standard protocols [28]. Blood samples were collected from 371 healthy women recruited as volunteer blood donors with an average age of 32.36 years. These volunteers were not matched by age with the patient group. Blood samples were also collected from 323 patients with clinical and histological confirmation of BC, and all of the patients were residents of the metropolitan area of Guadalajara. The patients were recruited from June 2010 to April 2012. All of the samples were obtained with the appropriate written informed consent and approval from the ethical committee 1305, Centro de Investigación Biomédica de Occidente, IMSS. Efforts were taken to ensure that siblings of those already sampled were excluded. Clinical and demographical data were obtained using written questionnaires. All of the patients were also interviewed to determine occupational exposure and the use of therapeutics.

Genotyping

The amplification of exon 8 in the CBS gene was performed by PCR using the following primers: 5’-CTGGCCTTGAGCCCTGAA-3’ derived from intron 7 and 5’-GGCCGGGCTCTGGACTC-3’ derived from intron 8 [11]. The PCR reactions were performed in a total volume of 15 µl containing 0.2 mM dNTPs (Invitrogen, Carlsbad, CA USA), 5 pmol of primers, 3.0 mM MgCl2, 2.5 U Taq polymerase (Invitrogen, Carlsbad, CA USA), and 0.8% bovine serum albumin (Promega, Madison, WI USA). The PCR conditions were 95°C (4 min) followed by 30 cycles of 95°C (1 min), 60°C (1 min), 72°C (2 min) and a final extension at 72°C (7 min). Using this procedure, we obtained fragments of 252 and 184 base pairs (bp). For 844ins68 allele discrimination, the amplified products were separated on 6% polyacrylamide gels (29 : 1) followed by silver staining [29]. We determined that the 184-bp fragment represented a wild-type genotype (W). Two fragments at 252 and 184-bp indicated a heterozygous genotype (W/Ins), and one fragment at 252-bp represented the genotype insertion of 68 bp (Ins/Ins).

To determine whether the individuals with the W/Ins and Ins/Ins 844ins68 polymorphism genotypes carried the T833C mutation in the same allele, 2 µl of the PCR products from intron 7 and exon 8 were subjected to restriction enzyme analysis with BsrI (New England Biolabs, Beverly, MA, USA) according to the manufacturer’s instructions, at 65°C for 12 h. After electrophoresis on an 8% polyacrylamide gel (19 : 1), the product was visualized by silver staining [29], which revealed the presence of allele 833C with 209- and 184-bp fragments [11].

Statistical analysis

Allele frequencies were obtained by direct counting. The Hardy-Weinberg equilibrium was tested by a goodness-of-fit $\chi^2$ test to compare the observed genotype frequencies to the expected frequencies among control subjects. Odds ratios and 95% confidence intervals (CI) were also calculated. A two-sided $p < 0.05$ was considered to be statistically significant. All statistical analyses were performed using PASW Statistic Base 18 software, 2009 (Chicago, IL).

Results

Demographic characteristic of study groups

Table I shows the comparative epidemiological data from the BC patients and the control individuals. In the patient group, the observed average age was 53.75 years, ranging from 28 to 88 years of age. Menarche had a mean age of 12.62 years in patients and 12.17 years in controls. Body mass index (BMI) ≥ 30–34.9 kg/m² (crude OR = 30.0, 95% CI: 10.9–83.5, $p < 0.0001$) and ≥ 35 kg/m² – > 40 kg/m² (OR = 12, 95% CI: 5.0–32.5, $p < 0.0001$), oral contraceptive use (OR = 2.5, 95% CI: 1.8–3.5, $p < 0.0001$), breastfeeding (OR = 2.7, 95% CI: 2.0–3.7, $p < 0.0001$), menopause (OR = 23.2, 95% CI: 15.1–35.8, $p < 0.0001$), familial history (FH) (OR = 2.9, 95% CI: 2.1–3.9, $p < 0.0001$) and maternal familial history (OR = 2.6, 95% CI: 1.8–3.6, $p < 0.0001$) were presented as risk factors.

Clinicopathological characteristics of BC patients

Table II shows the general clinical characteristics of the patient group. We observed that 26% of the patients had breast fibrosis and arterial hypertension (AH), approximately 40% were positive for hormonal receptors, 89% had ductal histology, and 62% had stage III–IV tumors. Approximately 20% of the patients had high levels of serum glutamate oxaloacetate transaminase (SGOT), alkaline phosphatase (ALP), GGT and glucose.

Table III summarizes the multivariate logistic regression analysis, where the BC group was classified as tumor stage I–II and III–IV as the dependent variables. The presence of menarche at 7–10 years of age. Menarche had a mean age of 12.62 years in patients and 12.17 years in controls. Body mass index (BMI) ≥ 30–34.9 kg/m² (crude OR = 30.0, 95% CI: 10.9–83.5, $p < 0.0001$) and ≥ 35 kg/m² – > 40 kg/m² (OR = 12, 95% CI: 5.0–32.5, $p < 0.0001$), oral contraceptive use (OR = 2.5, 95% CI: 1.8–3.5, $p < 0.0001$), breastfeeding (OR = 2.7, 95% CI: 2.0–3.7, $p < 0.0001$), menopause (OR = 23.2, 95% CI: 15.1–35.8, $p < 0.0001$), familial history (FH) (OR = 2.9, 95% CI: 2.1–3.9, $p < 0.0001$) and maternal familial history (OR = 2.6, 95% CI: 1.8–3.6, $p < 0.0001$) were presented as risk factors.
The association between the 844ins68 polymorphism in the CBS gene and breast cancer

Table I. Demographic data of the study groups

| Parameter                        | Breast cancer patients | Controls | OR (95% CI) | Value of p  |
|----------------------------------|------------------------|----------|-------------|-------------|
|                                  | n = 323 | % | n = 371 | % |                     |
| Age [years]                      |             |             |             |             |             |
| Mean (SD)                        | (53.75) | 11.17 | (32.36) | 9.57 | < 0.00011          |
| Menarche [years]                 |             |             |             |             |             |
| Mean (SD)                        | (12.62) | 1.6 | (12.17) | 1.07 | < 0.00011          |
| 7–10                             | (20) | 6 | (6) | 2 | 3.8 (1.5–9.7) | 0.002 |
| 11–13                            | (213) | 66 | (324) | 87 | 0.28 (0.19–0.41) | < 0.0001 |
| 14–18                            | (90) | 28 | (41) | 11 | 2.65 (1.7–3.9) | < 0.0001 |
| Body mass index (BMI)* [kg/m²]:  |             |             |             |             |             |
| 18.5–24.9 (normal)               | (84) | 26 | (202) | 55 | 0.29 (0.21–0.40) | < 0.0001 |
| ≥ 25–29.9 (overweight)           | (111) | 34 | (160) | 43 | 0.69 (0.50–0.93) | 0.018 |
| ≥ 30–34.9 (obesity I)            | (80) | 25 | (4) | 1 | 30 (10.9–83.5) | < 0.0001 |
| ≥ 35 – > 40 (obesity II–III)     | (48) | 15 | (5) | 1 | 12 (5.0–32.5) | < 0.0001 |
| Oral contraceptive use:          |             |             |             |             |             |
| Yes                              | (147) | 46 | (91) | 25 | 2.5 (1.8–3.5) | < 0.0001 |
| No                               | (176) | 54 | (280) | 75 |             |             |
| Breastfeeding:                   |             |             |             |             |             |
| Yes                              | (215) | 66 | (155) | 42 | 2.7 (2.0–3.7) | < 0.0001 |
| No                               | (108) | 34 | (216) | 58 |             |             |
| Menopause:                       |             |             |             |             |             |
| Postmenopausal                   | (222) | 69 | (32) | 9 | 23.2 (15.1–35.8) | < 0.0001 |
| Premenopausal                    | (101) | 31 | (339) | 91 |             |             |
| Tobacco consumption:             |             |             |             |             |             |
| Yes                              | (80) | 25 | (80) | 22 | 0.317 |
| No                               | (243) | 75 | (291) | 78 |             |             |
| Alcohol consumption:             |             |             |             |             |             |
| Yes                              | (64) | 20 | (95) | 26 | 0.07 |
| No                               | (259) | 80 | (276) | 74 |             |             |
| Familial history (FH)**:         |             |             |             |             |             |
| Yes                              | (198) | 61 | (132) | 36 | 2.9 (2.1–3.9) | < 0.0001 |
| No                               | (125) | 39 | (239) | 64 |             |             |
| Cancer type of FH:               |             |             |             |             |             |
| No                               | (125) | 39 | (239) | 64 | 0.3 (0.25–0.47) | < 0.0001 |
| Breast cancer                    | (41) | 13 | (16) | 4 | 3.2 (1.7–5.8) | < 0.0001 |
| Cancer + breast cancer           | (30) | 9 | (30) | 8 | 0.57 |
| Diabetes mellitus (DM)           | (27) | 8 | (56) | 15 | 0.51 (0.31–0.83) | 0.006 |
| Arterial hypertension (AH)       | (6) | 2 | (29) | 8 | 0.22 (0.09–0.54) | 0.0003 |
| DM-AH                            | (21) | 7 | (0) | 0 | 8.1 (1.0–66.9) | 0.019 |
| DM-AH-cancer                     | (73) | 22 | (1) | 1 | 108 (14.9–782) | < 0.0001 |
| Inheritance:                     |             |             |             |             |             |
| No                               | (125) | 39 | (239) | 65 | 0.3 (0.25–0.47) | < 0.0001 |
| Maternal                         | (125) | 39 | (72) | 19 | 2.6 (1.8–3.6) | < 0.0001 |
| Paternal                         | (33) | 10 | (36) | 10 | 0.82 |
| Both                             | (40) | 12 | (24) | 6 | 2.0 (1.2–3.4) | 0.007 |

*Fisher’s exact test. SD, standard deviation. *According to OMS classifications (Appropriate body mass index for Asian populations and its implications for policy and intervention strategies. Ginebra (Suiza): Organización Mundial de la Salud, 2004). **Positive familial history of cancer and leukemia in first and second degree relatives of patients.
Table II. Clinical data of patients with breast cancer

| Parameter                                | Breast cancer | n = 323 | %  |
|------------------------------------------|---------------|---------|----|
| Personal medical history:                |               |         |    |
| No                                       | 173           | 53      |    |
| DM-AH                                    | 83            | 26      |    |
| Breast fibrosis-AH                       | 21            | 7       |    |
| Hysterectomy, AH                         | 28            | 9       |    |
| Depression, pregnancy, preeclampsia      | 5             | 1       |    |
| Thrombosis                               | 7             | 2       |    |
| Hyperthyroidism                          | 6             | 2       |    |
| Tumor localization:                      |               |         |    |
| Right/left                               | 311           | 96      |    |
| Bilateral                                | 12            | 4       |    |
| BI-RADS                                   |               |         |    |
| Grade IV                                 | 239           | 75      |    |
| Grade V                                  | 84            | 26      |    |
| Diagnostic time [years]:                 |               |         |    |
| 1–4                                      | 215           | 67      |    |
| 5–9                                      | 100           | 31      |    |
| 10–15                                    | 8             | 2       |    |
| Tumor markers:                           |               |         |    |
| Luminal A                                | 140           | 43      |    |
| Luminal B                                | 86            | 27      |    |
| Triple negative                          | 53            | 16      |    |
| Her 2-neu                                | 44            | 14      |    |
| Histology                                |               |         |    |
| Ductal                                   | 288           | 89      |    |
| Lobular                                  | 28            | 9       |    |
| Mixed                                    | 7             | 2       |    |
| Tumor stage:                             |               |         |    |
| I–II                                     | 122           | 38      |    |
| III–IV                                   | 201           | 62      |    |
| Lymph node status:                       |               |         |    |
| Yes                                      | 241           | 75      |    |
| No                                       | 82            | 25      |    |
| Metastasis:                              |               |         |    |
| Yes                                      | 95            | 29      |    |
| No                                       | 228           | 71      |    |
| Metastasis site (n = 95)                 |               |         |    |
| Lung                                     | 7             | 7       |    |
| Bone                                     | 47            | 49      |    |
| Liver                                    | 3             | 3       |    |
| Bone-lung-liver                          | 36            | 39      |    |
| Lung-central nervous system              | 2             | 2       |    |
| Chemotherapy response:                   |               |         |    |
| Yes                                      | 223           | 69      |    |
| No                                       | 100           | 31      |    |

| Parameter                                | Breast cancer | n = 323 | %  |
|------------------------------------------|---------------|---------|----|
| Chemotherapy type:                       |               |         |    |
| FEC                                      | 264           | 82      |    |
| Other                                    | 45            | 14      |    |
| No chemotherapy                          | 14            | 4       |    |
| Chemotherapy toxicity:                   |               |         |    |
| Yes                                      | 255           | 79      |    |
| No                                       | 68            | 21      |    |
| Laboratory test:                         |               |         |    |
| Hemoglobin [g/dl]:                       |               |         |    |
| < 11                                     | 27            | 8       |    |
| 11–16.4                                  | 296           | 92      |    |
| Hematocrit (%):                          |               |         |    |
| < 37                                     | 58            | 18      |    |
| 37–47                                    | 265           | 82      |    |
| Platelets [mm³]:                         |               |         |    |
| < 450,000                                | 20            | 6       |    |
| 150,000–450,000                          | 208           | 64      |    |
| > 450,000                                | 95            | 30      |    |
| Leukocytes [mm³]:                        |               |         |    |
| < 150,000                                | 35            | 11      |    |
| 150,000–500,000                          | 288           | 89      |    |
| Urea [mg/dl]:                            |               |         |    |
| > 20                                     | 44            | 14      |    |
| 6–20                                     | 279           | 86      |    |
| Creatine [mg/dl]:                        |               |         |    |
| > 1.1                                    | 17            | 5       |    |
| 3–1.1                                    | 306           | 95      |    |
| Serum glutamate-oxaloacetate transaminase (SGOT) [mI/l]: | | | |
| > 35                                     | 68            | 21      |    |
| 0–35                                     | 255           | 79      |    |
| Serum glutamic pyruvic transaminase (SGPT) [µI/l]: | | | |
| > 45                                     | 53            | 16      |    |
| 5–45                                     | 270           | 84      |    |
| Lactate dehydrogenase (LDH) [µI/l]:      |               |         |    |
| > 333                                    | 60            | 19      |    |
| 105–333                                  | 263           | 81      |    |
| Alkaline phosphatase (ALP) [µI/l]:       |               |         |    |
| > 45                                     | 69            | 21      |    |
| 5–45                                     | 254           | 79      |    |
| γ-Glutamyltransferase (GGT) [µI/l]:      |               |         |    |
| > 45                                     | 70            | 22      |    |
| 5–45                                     | 253           | 78      |    |
| Glucose [µI/l]:                          |               |         |    |
| 74–106                                   | 65            | 20      |    |
| > 106                                    | 258           | 80      |    |

FEC – 5-fluorouracil, epirubicin, cyclophosphamide, others – paclitaxel, docetaxel, trastuzumab.
The association between the 844ins68 polymorphism in the CBS gene and breast cancer

Table III. The regression binary logistic of the breast cancer group

|                           | B       | SD      | Wald   | df | Value of p | OR     | 95% CI  |
|---------------------------|---------|---------|--------|----|------------|--------|---------|
|                           | Low     | Upper   |        |    |            |        |         |
| Menarche (7–10 years)     | 1.692   | 0.839   | 4.068  | 1  | 0.044      | 5.430  | 1.049   | 28.114 |
| No oral contraceptive use | -0.743  | 0.337   | 4.864  | 1  | 0.027      | 0.476  | 0.246   | 0.921  |
| Tobacco (consumption)     | 0.937   | 0.415   | 5.096  | 1  | 0.024      | 2.552  | 1.131   | 5.756  |
| Familial history (absence)| -1.407  | 0.595   | 5.582  | 1  | 0.018      | 0.245  | 0.076   | 0.787  |
| Chemotherapy (FEC)        | 1.009   | 0.450   | 4.864  | 1  | 0.025      | 2.743  | 1.135   | 6.627  |
| Lymph node status         | 1.054   | 0.386   | 7.461  | 1  | 0.006      | 2.869  | 1.347   | 6.112  |
| Constant                  | 67.03   | 70843   | 0.000  | 1  | 0.999      | 1.293  |         |        |

Variables included in the analysis: dependent: breast cancer patients classified by tumor status as I–II and III–IV. Independent: personal medical history, menarche ranges 7–10 years, 11–13 years, 14–18 years; menopause, pregnancies, breastfeeding, oral contraceptive use, tobacco and alcohol consumption, HF, HF type: breast cancer, DM, AH, DM-AH-cancer, parental inheritance: mother, father, both, and BMI: 18.5–24.9, ≥25–29.9, ≥30–34.9, ≥35–> 40 kg/m², years of diagnosis; BI-RADS, histology, tumor markers, lymph node status, metastasis, MTS tissue, response to chemotherapy, type of chemotherapy, toxicity in chemotherapy, laboratory tests (HB, HTO, platelets, leukocytes, urea, creatinine, SGOT, SGPT, LDH, ALP, GGT and glucose).

Table IV. Genotype and allelic distribution of the 844ins68/T833C CBS polymorphism** in healthy controls and breast cancer patients

| Genotypes      | Groups                      | Patients (n = 323) | Controls* (n = 371) | Patients vs. controls |
|----------------|-----------------------------|-------------------|---------------------|----------------------|
|                | n   | %  | n   | %  | OR   | 95% CI | Value of p |
| W/W            | 233 | 72 | 320 | 86 | 0.41 | 0.28–0.60 | 0.001       |
| W/Ins          | 83  | 26 | 49  | 13 | 2.2  | 1.5–3.3   | 0.0001      |
| Ins/Ins        | 7   | 2  | 2   | 1  | 4.0  | 0.84–19.8 | 0.05        |
| W/Ins and Ins/Ins | 90  | 28 | 51  | 14 | 2.4  | 1.6–3.5   | 0.0001      |
| Alleles:       |     |    |     |    |      |         |            |
| W              | 549 | 0.85 | 689 | 0.93 | 0.43 | 0.30–0.61 | 0.0001      |
| Ins            | 97  | 0.15 | 53  | 0.07 | 2.2  | 1.6–3.2   | 0.0001      |

*Hardy-Weinberg equilibrium in the controls (X² = 0.015; p = 0.90); **Marker informativity 0.87 was assessed within a range of 0–1; markers with a score greater than 0.7 were considered to be highly informative, whereas markers with a value of 0.44 were considered to be moderately informative [6].

6.6, p = 0.025) and nodule metastatic (OR = 2.8, 95% CI: 1.3–6.1, p = 0.006) were risk factors. In contrast, not using oral contraceptives (OR = 0.47, 95% CI: 0.24–0.92, p = 0.027) and the absence of a familial history of cancer (OR = 0.24, 95% CI: 0.07–0.78, p = 0.018) were protection factors.

Frequency of 844ins68 polymorphism of CBS gene between study groups

Co-segregation of the 844ins68 and T833C polymorphisms were observed in the controls and patient groups. For that reason, we just present the 844ins68 polymorphism data in Table IV. The W/W genotype was observed in 72% (233/323) of patients compared with 86% (320/371) of the controls (OR = 0.41, 95% CI: 0.28–0.60, p = 0.001). The heterozygous genotype (W/Ins) was observed in 26% of the patients (83/323) and 13% (49/371) of the controls (OR = 2.2, 95% CI: 1.5–3.3, p = 0.0001). The polymorphic genotype (Ins/Ins) was observed in 2% (7/323) of the controls and in 1% (2/371) of the patients (p = 0.05). All of the genotype distributions were in Hardy-Weinberg equilibrium. All of the samples were analyzed, and all of the genotypes (373 controls and 232 BC patients) were obtained. In addition, no differences were found with regard to the general characteristics of the study groups and 844ins68/T833C CBS polymorphisms, except that the absence of metastatic lymph was associated with the genotype W/W (OR = 0.430, 95% CI: 0.21–0.85, p = 0.015) as a protective factor.

Comparison between heterozygous genotype patients with clinical-pathologic characteristics of BC patients

Table V shows that the patients with the heterozygous genotype were associated with more than one variable listed in Table I and II. The heterozygous patients who had undergone menopause...
Table V. Association of the 844ins68/T833C CBS polymorphism with more than one variable of the general characteristics of the breast cancer patients

| Variable                        | Polymorphism       | Menarche (7–10 years) | Value of p  |
|---------------------------------|--------------------|-----------------------|-------------|
|                                 |                    | Yes, n               | No, n | OR      | 95% CI     |
| Menopause                       | W/Ins-Ins/Ins     | 3                     | 21     | 10.85   | (1.07–109.8) | 0.040 |
|                                 | W/W                | 1                     | 76     |          |            |       |
| GGT levels                      | High               | W/Ins-Ins/Ins        | 20     | 2.17    | (1.1–4.26)  | 0.02  |
|                                 | Normal             | W/Ins-Ins/Ins        | 26     | 1.97    | (1.05–3.69) | 0.031 |
|                                 |                    | W/W                  | 38     | 2.2     | (1.08–4.47) | 0.027 |
| Alcohol consumption             | Yes                | W/Ins-Ins/Ins        | 9      | 3.1     | (1.17–8.49) | 0.019 |
|                                 | No                 | W/W                  | 13     | 1.97    | (1.05–3.69) | 0.031 |
| Diagnostic [years]              |                    | W/Ins-Ins/Ins        | 24     | 2.2     | (1.08–4.47) | 0.027 |
|                                 |                    | W/W                  | 38     | 1.97    | (1.05–3.69) | 0.031 |
| LDH serum levels                | High               | W/Ins-Ins/Ins        | 17     | 4.2     | (1.2–4.8)  | 0.007 |
|                                 | Normal             | W/Ins-Ins/Ins        | 23     | 4.2     | (1.2–4.8)  | 0.007 |
|                                 |                    | W/W                  | 38     | 1.97    | (1.05–3.69) | 0.031 |
| GGT levels                      | High               | W/Ins-Ins/Ins        | 21     | 2.2     | (1.08–4.47) | 0.027 |
|                                 | Normal             | W/Ins-Ins/Ins        | 23     | 2.2     | (1.08–4.47) | 0.027 |
|                                 |                    | W/W                  | 38     | 1.97    | (1.05–3.69) | 0.031 |
| Diagnosis [years]               |                    | W/Ins-Ins/Ins        | 24     | 2.2     | (1.08–4.47) | 0.027 |
|                                 |                    | W/W                  | 38     | 1.97    | (1.05–3.69) | 0.031 |
| BMI                             | ≥ 30 – > 40        | W/Ins-Ins/Ins        | 26     | 2.07    | (1.1–3.86)  | 0.021 |
|                                 |                    | W/W                  | 41     | 2.2     | (1.08–4.47) | 0.027 |
| Tumor stage                     | III–IV             | W/Ins-Ins/Ins        | 23     | 3.2     | (1.2–8.3)  | 0.013 |
|                                 | I–II               | W/W                  | 41     | 3.2     | (1.2–8.3)  | 0.013 |

were associated with menarche (7–10 years) (OR = 10.85, 95% CI: 1.07–109.8, p = 0.040) and elevated levels of the enzyme GGT (OR = 2.17, 95% CI: 1.1–4.26, p = 0.02) as risk factors.

The heterozygous patients with stage I–II tumors were associated with alcohol consumption (OR = 3.1, 95% CI: 1.17–8.49, p = 0.019). The heterozygous patients who responded to chemotherapy showed an association with the following: 1) the diagnosis of 5–9 years (OR = 1.97, 95% CI: 1.05–3.69, p = 0.031), high levels of LDH (OR = 2.2, 95% CI: 1.08–4.47, p = 0.027), and high levels of GGT (OR = 2.4, 95% CI: 1.2–4.8, p = 0.007). Heterozygous patients with a BMI of 18.5–30 kg/m²
The association between the 844ins68 polymorphism in the CBS gene and breast cancer

and ≥ 30 kg/m² – > 40 kg/m² were associated with the diagnosis of 5–9 years (OR = 2.07, 95% CI: 1.1–3.86, p = 0.021), and tumor stage III–IV (OR = 3.2, 95% CI: 1.2–8.3, p = 0.013).

**Discussion**

In Mexico, BC is considered to be a major health population issue because it is currently one of the leading causes of death in productive age women [4, 5]. These facts are consistent with our observations in the current study, wherein the average age was 53.75 ±11.17, early menarche (7–10 years), BMI obesity II–III (≥ 30 kg/m² to > 40 kg/m²), menopause status, familial history of cancer, diabetes mellitus (DM) and hypertension were observed as risk factors. These observations have been observed in other reports [30–36]. Breastfeeding was recorded in 66% of the patients in contrast with 42% of the controls, which made it a risk factor. However, these results should be taken with caution, because they did not consider the period of lactation. It is hypothesized that prolonged breastfeeding reduces the risk of BC, and that risk is reduced by 4% for each 12 months of breastfeeding [37]. One study estimated that approximately 3% of breast cancers in UK women were associated with breastfeeding for less than 6 months [38].

When the BC group was stratified by tumor stage, as either I–II or III–IV, and compared with the clinical and biochemical characteristics of BC, early menarche (7–10 years), contraceptive hormonal use, familial history, tobacco consumption, metastasis to lymph nodes, and chemotherapy type (FEC) emerged as risk factors. The association of tobacco use with BC is still controversial, and one study showed that smokers had a BC risk of 10–20% compared to nonsmokers [38–40]. This association depends on the number of cigarettes smoked per day and exposure time; however, in most studies, these parameters are not considered. In this regard, in our study, patients with stage III–IV tumors who smoked had increased risk, and our data are consistent with previous reports [39, 40]. Also, the presence of lymph node metastases and chemotherapy type were risk factors for BC patients with stage III–IV tumors. In fact, the BC tumor stage is important for determining treatment, and a predictor of survival. There is evidence that patients with micrometastases in axillary lymph nodes have an increased risk of distant metastases compared to patients without axillary lymph node metastases [39].

Among factors that can favor carcinogenesis are individual genetic variations for susceptibility. Polymorphisms, which are low penetrance genes, are risk factors in cancer [40–44]. Folate metabolism has been proposed to be a contributing factor, by promoting DNA hypomethylation of key regulatory genes and uracil misincorporation into DNA, which leads to double-strand breaks and chromosomal aberrations [45]. The biochemical effect of the 844ins68 polymorphism has been associated with either low levels of homocysteine and methionine [46, 47], or high levels of homocysteine [48] when it co-segregates in cis with T833C [46–49]. Our findings are consistent with co-segregation because we observe similar frequencies of both the 844ins68 and the T833C polymorphisms. In the literature, several population frequencies of 844ins68 have been published [12–25]. Little is known about the association of this polymorphism with BC in our population; the allelic frequency of this polymorphism was 0.07 in controls and 0.15 in BC patients and was associated as a risk factor. However, a study observed the association between 844ins68 polymorphism with lower survival in neck cancer [49].

A possible explanation could be that CBS enzyme catalyzes the condensation of homocysteine with serine to give rise to cystathionine as a precursor of cysteine. The CBS deficiency can alter the stability of a domain or residue in the hydrophobic core, which leads to degradation of the protein and produces elevated plasma homocysteine and methionine leading to genomic DNA hypomethylation [50]. This may potentially have an impact on BC oncogenesis.

Although the sample representing the association of the W/Ins-Ins/Ins genotype, as a risk factor in postmenopausal patients presenting early menarche, was small, this association was observed in this study, and probably both prolonged exposure to estrogens and nutritional status could be the explanation; however, there is no evidence in the literature of this association. Another possible explanation is that given folates are involved in DNA methylation [9, 44], variations in genes of this pathway, such as the CBS gene, may cause poor metabolism of folate and may alter DNA methylation patterns and influence the expression, integrity and stability of DNA [9]. Moreover, alteration in the levels of folate may have an effect on other metabolic pathways, such as the estrogen pathway. Zhu et al. postulated that a folate and methionine deficiency may be associated with BC because of methylation of the estrogen receptor gene’s CpG islands [51]; this finding is related to the lack of gene expression in breast tumors that are positive for the estrogen receptor.

We also observed the association of the W/Ins-Ins/Ins genotype in postmenopausal patients with elevated levels of GGT as a risk factor. This observation could possibly be explained by the participation of GGT in cellular glutathione metabolism, modulated redox reactions and its reconstitution.

Arch Med Sci 6, December / 2014 1221
of cellular antioxidant, anticystic defense, cell proliferation, apoptosis, tumor progression, invasion and cancer cell drug resistance. The expression of GGT is often increased in tumors and has been suggested to be a biomarker [52–54]. The GGT enzyme is expressed constitutively in various organs and rises significantly in premalignant lesions or malignant tumors; therefore, it is considered to confer a favorable environment for the growth and survival of neoplastic cells [52]. This study provides new data for alcohol consumption as a risk factor, because of the observed association between the W/Ins-Ins/Ins CBS genotype in BC with tumor stage I–II and alcohol consumption. It is known that alcohol increases the endogenous levels of estrogen, which is a known risk factor for BC [55].

The response to chemotherapy in BC patients with evolution from 5 to 9 years and elevation of LDH and GGT enzymes were influenced by the W/Ins-Ins/Ins CBS genotype in this study; but it is well known that the response to chemotherapy depends on several factors. Adjuvant chemotherapy can induce persistent resistance to the drugs with longer exposure, and the anthracyclines have achieved longer time to progression and survival time compared with cyclophosphamide/methotrexate/5-fluorouracil-based chemotherapy [56].

In contrast, it has been observed that high expression of LDH and GGT is indicative of a poor response in patients with BC at later stages. The elevated expression of these enzymes is thought to reflect tumor aggressiveness [57]. Another factor that may influence the response to chemotherapy is menopause, which is associated with a less favorable response [58]. However, there are no studies concerning the influence of the W/Ins-Ins/Ins CBS genotype and the response to chemotherapy depending on the overexpression of the LDH and GGT enzymes.

The W/Ins-Ins/Ins genotype is a risk factor in BC patients with a BMI ≥ 29.9 kg/m² – > 40 kg/m² who were diagnosed in 5 to 9 years, have advanced tumor stage (III–IV) and have an inherited family history. Obesity is a major risk factor for developing BC in postmenopausal women. Weight gain in women with postmenopausal BC in industrialized countries has a significant impact on health [59]. Several studies have reported that women who are obese at diagnosis have an increased risk of lymph node metastasis [60]. In fact, there are several theories that attempt to explain this association, involving the role of leptin, insulin and other molecules that mediate the inflammatory process independently of estrogen. In addition, peripheral circulating estrogens are elevated in obese postmenopausal women. Another current hypothesis proposes that obesity is associated with metabolic syndrome, which activates molecular processes that are mitogenic in breast epithelial cells and stimulate neoplasia. A third proposal suggests that adipocytes and their autocrine mechanisms are important for BC development [32].

Several hypotheses have been proposed to try to explain this association, which influences growth and BC prognosis. It has been suggested that adipocytes are now recognized as active endocrine cells that produce hormones, growth factors and cytokines. In fact, the most likely scenario is that all of these mechanisms may combine to explain the relationship linking menopause and subsequent weight gain in BC [60–62].

In conclusion, the 844ins68/T833C CBS polymorphism contribute significantly to BC susceptibility in: 1) menopause and high GGT levels, 2) chemotherapy type and high LDH levels, 3) chemotherapy type and high GGT levels, and 4) BMI and III–IV tumor stage, in the analyzed sample from the Mexican population, but further studies are required to confirm or reject these observations.

Acknowledgments

This study was supported by grant from FIS/IMSS/PROT/G13/1231.

References

1. Bandi MS, Brinton L, Buchert S, et al. Breast cancer facts and figures 2009-2010. American Cancer Society, [http://www.cancer.org/acs/groups/content/@nho/documents/document/f861009final90809pdfpdf.pdf].
2. Siegel R, Desantis C, Virgo K, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 2012; 62: 220-241.
3. Miller JW, King JB, Joseph DA, Richardson LC. Breast cancer screening among adult women – behavioral risk factor surveillance system, United States, 2010. MMWR Surveill Summ 2012; 61: 46-50.
4. Mortalidad de cáncer de mama: [http://wwwnc.cenegob.gob.mx/programas/cancer-mama/mortalidad-cancer-de-mama.html]
5. Knaul FM, Nigenda G, Lozano R, Arreola R, Langer A, Frenk J. Breast cancer in Mexico: an urgent priority. Salud Publica Mex 2009; 51 (Suppl. 2): 335-44.
6. Gallegos MP, Valencia LE, Puebla AM, Figuera LE, Zúñiga GM. The TPS3 16-bp duplication polymorphism is enriched in endometriosis patients. Gynecol Obstet Invest 2012; 73: 118-23.
7. Abdulrahman GO Jr, Rahman GA. Epidemiology of breast cancer in Europe and Africa. J Cancer Epidemiol 2012; 2012: 915610.
8. Kraus JP, Oliveriusova J, Sokolova J, et al. The human cystathionine beta-synthase (CBS) gene: complete sequence, alternative splicing, and polymorphisms. Genomics 1998; 52: 312-24.
9. Galbiatti AL, Ruiz MT, Raposo LS, Maniglia JV, Pavani-No-Bertelli EC, Goloni-Bertalto EM. The association between CBS 844ins68 polymorphism and head and neck squamous cell carcinoma risk – a case-control analysis. Arch Med Sci 2010; 6: 772-9.
10. Sebastio G, Sperandeo MR Panico M, de Franchis R, Kraus JP, Andria G. The molecular basis of homocystin-
The association between the 844ins68 polymorphism in the CBS gene and breast cancer

uria due to cystathionine beta-synthase deficiency in Italian families, and report of four novel mutations. Am J Hum Genet 1995; 56: 1324-33.

11. Tsai M, Bignell M, Schwickert K, Hanson NQ. High prevalence of a mutation in the cystathionine beta-synthase gene. Am J Hum Genet 1996; 59: 1262-7.

12. Sharp L, Little J. Polymorphisms in genes involved in folate metabolism and colorectal neoplasia: a HuGe review. Am J Epidemiol 2004; 159: 423-43.

13. Pepe G, Vanegas OC, Rickards O, et al. World distribution of the T838C/844INS68 CBS in cis double mutation: a reliable anthropological marker. Hum Genet 1999; 104: 126-9.

14. De Stefano V, Dekou V, Nicaud V, et al. Linkage disequilibrium at the cystathionine beta synthase (CBS) locus and the association between genetic variation at the CBS locus and plasma levels of homocysteine. The Ears II Group. European Atherosclerosis Research Study. Ann Hum Genet 1998; 62: 481-90.

15. Kluitjmtms LA, Boers GH, Trijbels FJ, van Lith-Zanders HM, van den Heuvel LP, Blom HJ. A common 844INS68 insertion variant in the cystathionine beta-synthase gene. Biochem Mol Med 1997; 62: 23-5.

16. Grossmann R, Schwender S, Gelsen U, Schambeck C, Merati G, Walter U, CBS 844ins68, MTHFR TT677 and EPCR 4031Ins23 genotypes in patients with deep-vein thrombosis. Thromb Res 2002; 107: 13-5.

17. Urreizti R, Asteggiano C, Vilaseca MA, et al. A CBS haplotype and a polymorphism at the MSR gene are associated with cardiovascular disease in a Spanish case-control study. Clin Biochem 2007; 40: 864-8.

18. Rai PS, Murali TS, Vasudevan TG, et al. Genetic variation in genes involved in folate and drug metabolism in a south Indian population. Indian J Hum Genet 2011; 17 (Suppl. 1): 48-53.

19. Vyletal P, Sokolová J, Cooper DN, et al. Diversity of cystathionine beta-synthase haplotypes bearing the most common homocystinuria mutation c833T>C: a possible role for gene conversion. Hum Mutat 2007; 28: 255-64.

20. Senemar S, Doroudchi M, Pezeshki AM, Bazrgar M, Torabi-sarvestani A, Ghaderi A. Frequency of cystathionine beta-synthase 844ins68 polymorphism in Southern Iran. Mol Biol Rep 2009; 36: 553-6.

21. Zhang G, Dai C. Gene polymorphisms of homocysteine metabolism-related enzymes in Chinese patients with occlusive coronary artery or cerebral vascular diseases. Thromb Res 2001; 104: 187-95.

22. Gutiérrez JJ, Pérez F, Tamparillas M, et al. Polymorphisms in cystathionine beta-synthase and methylene tetrahydrofolate reductase genes as risk factors for cerebral vascular disease. Med Clin 2005; 124: 281-4.

23. Guzmán N, Salazar L. Asociación de variantes funcionales en genes del metabolismo de la homocisteína con riesgo de trombosis venosa profunda e hiperhomocisteinemia en individuos del Sur de Chile. Rev Chil Cardiol 2011; 30: 28-32.

24. Speer MC, Nye J, McLone D, et al. Possible interaction of genotypes at cystathionine beta-synthase and methylene tetrahydrofolate reductase (MTHFR) in neural tube defects. NTD Collaborative Group. Clin Genet 1999; 56: 142-4.

25. Alves Jacob M, da Cunha Bastos C, Regina Bonini-Domingos C. The 844ins68 cystathionine beta-synthase and C677T MTHFR gene polymorphism and the vsa-occlusive event risk in sickle cell disease. Arch Med Sci 2011; 7: 97-101.

26. Weiner AS, Boyarskikh UA, Voronina EN, et al. Polymorphisms in the folate-metabolizing genes MTR, MTRR, and CBS and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2007; 16: 1140-7.

27. Stevens VL, McCullough ML, Pavluck AL, et al. Association of polymorphisms in one-carbon metabolism genes and postmenopausal breast cancer incidence. Cancer Epidemiol 2012; 36: 95-100.

28. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 6: 1215.

29. Sanguineti CI, Dias NE, Simpson AI. Rapid silver staining and recovery of PCR products separated on polyacrylamide gels. Biotechniques 1994; 17: 914-21.

30. Naieni KH, Ardalan A, Mahmoodi M, Motavalian A, Yahyapoor Y, Yazdizadeh B. Risk factors of breast cancer in north of Iran: a case-control in Mazandaran Province. Asian Pac J Cancer Prev 2007; 8: 395-8.

31. Henderson BE, Roos RK, Judd HL. Regular ovulatory cycles do increase breast cancer risk? Cancer 1985; 56: 1206-8.

32. Macciò A, Madeddu C. Obesity, Inflammation, and post-menopausal breast cancer: therapeutic implications. Sci World J 2011; 11: 2020-36.

33. Chlebowski RT, Anderson GL, Gass M, et al. WHI Investigators. Estrogen plus progesterone and breast cancer incidence and mortality in postmenopausal women. JAMA 2010; 304: 1684-92.

34. Collaborative Group on Hormonal Factors in Breast Cancer and hormonal contraceptives: collaborative re-analysis of data on 53 297 Single Women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 1996; 347: 1717-27.

35. Lazzcano EC, Tovar V, Alonso P, Romieu I, Lopez L. Breast cancer. A historical theme, present and future. J Public Health 1996; 38: 139-52.

36. Parkin DM. Cancers attributable to reproductive factors in the UK in 2010. Br J Cancer 2011; 105 (S2): S73-6.

37. Lipworth L, Bailey R, Trichopoulos D. History of breast-feeding in relation to breast cancer risk: a review of the epidemiologic literature. J Natl Cancer Inst 2000; 92: 942-3.

38. Xue F, Willett WC, Rosner BA, Hankinson SE, Michels KB. Cigarette smoking and the incidence of breast cancer. Arch Intern Med 2011; 171: 125-33.

39. Hwang RE, Gonzalez-Angulo AM, Yi M, et al. Low locoregional failure rates in selected breast cancer patients with tumor-positive sentinel lymph nodes who do not undergo completion axillary dissection. Cancer 2007; 110: 723-30.

40. Gallegos MP, Figuera LE, Troyo R, et al. CYP1A1 *2B and *4 polymorphisms are associated with lung cancer susceptibility in Mexican patients. Int J Biol Markers 2008; 23: 24-30.

41. Lightfoot TJ, Johnston WT, Painter D, et al. United Kingdom Childhood Cancer Study. Genetic variation in the folate metabolic pathway and risk of childhood leukemia. Blood 2010; 115: 3923-9.

42. Hosseini M, Houshmand M, Ebrahimi A. MTHFR polymorphisms and breast cancer risk. Arch Med Sci 2011; 7: 134-7.

43. Mojgan H, Massoud H, Ahmad E. ERCC1 intron 1 was a reliable anthropological marker. Hum Genet 1999; 62: 481-90.

44. van den Heuvel LP, Blom HJ. A common 844INS68 insertion variant in the DNA mismatch repair gene hMSH2 and postmenopausal breast cancer. Ann Intern Med 2000; 132: 598-604.

45. Stevenson AD, Jones SE, Boedeker CA, et al. EPCR 4031Ins23 genotypes in patients with deep-vein thrombosis. Thromb Res 2001; 104: 126-9.

46. Senemar S, Doroudchi M, Pezeshki AM, Bazrgar M, Torabi-sarvestani A, Ghaderi A. Frequency of cystathionine beta-synthase 844ins68 polymorphism in Southern Iran. Mol Biol Rep 2009; 36: 553-6.

47. Zhang G, Dai C. Gene polymorphisms of homocysteine metabolism-related enzymes in Chinese patients with occlusive coronary artery or cerebral vascular diseases. Thromb Res 2001; 104: 187-95.

48. Gutiérrez JJ, Pérez F, Tamparillas M, et al. Polymorphisms in cystathionine beta-synthase and methylene tetrahydrofolate reductase genes as risk factors for cerebral vascular disease. Med Clin 2005; 124: 281-4.

49. Guzmán N, Salazar L. Asociación de variantes funcionales en genes del metabolismo de la homocisteína con riesgo de trombosis venosa profunda e hiperhomocisteinemia en individuos del Sur de Chile. Rev Chil Cardiol 2011; 30: 28-32.

50. Speer MC, Nye J, McLone D, et al. Possible interaction of genotypes at cystathionine beta-synthase and methylene tetrahydrofolate reductase (MTHFR) in neural tube defects. NTD Collaborative Group. Clin Genet 1999; 56: 142-4.

51. Alves Jacob M, da Cunha Bastos C, Regina Bonini-Domingos C. The 844ins68 cystathionine beta-synthase and C677T MTHFR gene polymorphism and the vsa-occlusive event risk in sickle cell disease. Arch Med Sci 2011; 7: 97-101.
45. Griffioen PH, de Jonge R, van Zelst BD, Brouns RM, Lindemans J. Detection and allele-frequencies of the 833T.C, 844ins68 and a novel mutation in the cystathionine b-synthase gene. Clin Chim Acta 2005; 354: 191-4.

46. Dekou V, Gudnason V, Hawe E, Miller GJ, Stansbie D, Humphries SE. Gene-environment and gene-gene interaction in the determination of plasma homocysteine levels in healthy middle-aged men. Thromb Haemost 2001; 85: 67-74.

47. Tsai MY, Yang E Bignell M, Aras Q, Hanson NQ. Relationship between plasma homocysteine concentration, the 844ins68 variant of the cystathionine beta-synthase gene, and pyridoxal-5'-phosphate concentration. Mol Genet Metab 1999; 67: 352-6.

48. Summers CM, Hammons AL, Mitchell LE, et al. Influence of the cystathionine beta-synthase 844ins68 and methylenetetrahydrofolate reductase 677C>T polymorphisms on folate and homocysteine concentrations. Eur J Hum Genet 2008; 16: 1010-3.

49. Galbiatti AL, da Silva LM, Ruiz-Cintra MT, et al. Association between 11 genetic polymorphisms in folate-metabolising genes and head and neck cancer risk. Eur J Cancer 2012; 48: 1525-53.

50. Tsai MY, Bignell M, Yang E, Welge BG, Graham KJ, Hanson NQ. Polygenic influence on plasma homocysteine: association of two prevalent mutations, the 844ins68 of cystathionine beta-synthase and A(2756)G of methionine synthase, with lowered plasma homocysteine levels. Atherosclerosis 2000; 149: 131-7.

51. Zhu K, Williams SM. Methyl-deficient diets, methylated er genes and breast cancer: an hypothesized association. Cancer Causes Control 1999; 9: 615-20.

52. Pomella A, De Tata V, Paolicchi A, Zunino F. Expression of gamma-glutamyltransferase in cancer cells and its significance in drug resistance. Biochem Pharmacol 2006; 71: 231-8.

53. Van Hemelrijck M, Jassem W, Walldius G, et al. Gamma-glutamyltransferase and risk of cancer in a cohort of 545,460 persons – the Swedish AMORIS study. Eur J Cancer 2011; 47: 2033-41.

54. Fentiman IS, Allen DS. gamma-Glutamyltransferase and breast cancer risk. Br J Cancer 2010; 103: 90-3.

55. Hvidtfeldt UA, Gunter MJ, Lange T, et al. Quantifying mediating effects of endogenous estrogen and insulin in the relation between obesity, alcohol consumption, and breast cancer. Cancer Epidemiol Biomarkers Prev 2012; 21: 1203-12.

56. Milton F 4th, Ray CE Jr, Messersmith W. Chemotherapy agents: a primer for the Interventional radiologist. Semin Intervent Radiol 2010; 27: 384-90.

57. Cao R, Wang LP. Serological diagnosis of liver metastasis in patients with breast cancer. Cancer Biol Med 2012; 9: 57-62.

58. Schiavon G, Gupta GP, Redana S, Santini D. Heterogeneity of breast cancer: gene signatures and beyond. In: Diagnostic, prognostic and therapeutic value of gene signatures. Russo A, Iacobellis S, Iovanna J (ed.). Springer Science 2012; 13-25.

59. Ericson U, Sonestedt E, Ivarsson MI, et al. Folate intake, methylenetetrahydrofolate reductase polymorphisms, and breast cancer risk in women from the Malmo diet and cancer cohort. Cancer Epidemiol Biomarkers Prev 2009; 18: 1101-10.

60. Chen S, Chen CM, Zhou Y, Zhou RJ, Yu KQ, Shao ZM. Obesity or overweight is associated with worse pathological response to neoadjuvant chemotherapy among Chinese women with breast cancer. PLoS One 2012; 7: e41380.